Drugs / BPI-442096
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05369312 | Jun 2022 → May 2024 | colorectal cancer, malignant pancreatic neoplasm, non-small cell lung carcinoma | Betta Pharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-05-20 | Betta Pharmaceuticals Co., Ltd. | Regulatory 贝达药业SHP2抑制剂BPI-442096在美国获批临床 bettapharma.com ↗
5月20日，贝达药业控股美国子公司Xcovery Holdings, Inc.（以下简称“Xcovery”）收到美国食品药品监督管理局（FDA）通知，Xcovery申报的BPI-442096片拟用于晚期实体瘤的药品临床试验申请已获得美国FDA批准。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-05-20 | Betta Pharmaceuticals Co., Ltd. | 贝达药业SHP2抑制剂BPI-442096在美国获批临床 bettapharma.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BPI-442096 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05369312 ↗ |
| Action | Inhibit | “BPI-442096, a SHP2 inhibitor” NCT05369312 ↗ |
| Route | Oral | “Oral tablets taken in escalating levels” NCT05369312 ↗ |